Significant progress in the genome sequencing process has given scientists in England. A closer view of how much possible cancer to be developed, based on the mixture of who your ancestors are and which behavior you do personally. Based on the data provided by the 100,000 genome project, which was sorted and analyzed more than 85,000 NHS participants in December 2018, Cambridge University Professor Serena Nik-Zainal reported new findings on April 21, 2022, which showed the discovery of 58 mutual signatures “which theoretically can help the doctor better determine it is better to determine it is better to determine it is better to determine it better determine it better determine the determination better determine the doctor theoretically, the cause of cancer under certain circumstances.
Most likely, the gift of knowledge found in this finding so far only serves to show that there is an additional mutation signature to be found with further research, which can make certain cancer more easily detected early. According to formal reports published in Science, Nik-Zainal and his team in Cambridge have analyzed data from 18,640 total cancers using the entire sequencing process of genomes, or WGS, noting that there is still a lot of room for the discovery of researchers at the NHS clearly likes to see the data produced by the 100,000 genome project is used well.
Professor Matt Brown of Genomics England spoke with Cambridge, saying, “Signature mutation is an example of using the full potential of WGS. We hope to use the mutation instructions that are seen in this study and apply it back to our patient population, with the highest aim of increasing diagnosis and management cancer patients. “
How this cambridge study encourages future cancer research
One of the biggest takeaways of recent research is the development of a new genome sorting algorithm called multi-step fitting fitting fit, or Fitms, which is designed for the order of cancer cross references at high speed. According to science, Fitms detected special signature of organs and compared it with “additional rare signatures.” When applied, this can take some severe appointments from the sequence of new cancer data samples, which should make more simple cancer research.
The current genomic analysis is not the main part of cancer assessment if the report from science is an indication. However, it seems that this progress can make such methods more common, and it can be translated into better cancer patients in the NHS clinic in the near future. Sequencing all genomes is one of two processes that can be considered “sequencing the next generation,” according to the technology network. This is the first sequencing method that can sort the entire genome, which can allow deeper insights about genomes than alternative methods, intact sequences, which only target the genome protein code area.